Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent comments from Pfizer 's (NYSE: PFE) CEO, Albert Bourla, suggest it could become ...

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major Eli Lilly for the development of therapeutics by utilizing ABL Bio’s Grabody ...

SEOUL, Nov. 19 (Yonhap) -- Celltrion Inc., South Korea's leading biopharmaceutical company, said Wednesday it will invest 4 trillion won (US$2.7 billion) in the country to expand its domestic ...

Novo Nordisk is rated a 'Strong Buy' due to its undervaluation, wide economic moat, and long-term growth prospects despite ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer expressed his thoughts on. A caller asked, as a long-time holder ...

Novo Nordisk, the Danish pharmaceutical company that has long dominated the obesity treatment market, significantly lowered ...

Major stock indexes ended sharply lower to begin the week, which will see AI darling Nvidia and retail giants report ...

Eli Lilly shares have room to keep going as GLP-1 drugs spread their reach.

DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, ...